- Previous Close
25.65 - Open
25.68 - Bid 26.46 x 1000
- Ask 26.47 x 900
- Day's Range
25.61 - 26.56 - 52 Week Range
24.82 - 34.60 - Volume
1,683,067 - Avg. Volume
1,331,787 - Market Cap (intraday)
3.607B - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-0.83 - Earnings Date Aug 2, 2024
- Forward Dividend & Yield 1.10 (4.30%)
- Ex-Dividend Date Aug 30, 2024
- 1y Target Est
35.67
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
www.perrigo.com9,140
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PRGO
View More
Performance Overview: PRGO
Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRGO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRGO
View MoreValuation Measures
Market Cap
3.50B
Enterprise Value
7.02B
Trailing P/E
2.75k
Forward P/E
9.10
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.79
Price/Book (mrq)
0.77
Enterprise Value/Revenue
1.58
Enterprise Value/EBITDA
22.95
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.81%
Return on Assets (ttm)
1.20%
Return on Equity (ttm)
-2.42%
Revenue (ttm)
4.43B
Net Income Avi to Common (ttm)
-113.8M
Diluted EPS (ttm)
-0.83
Balance Sheet and Cash Flow
Total Cash (mrq)
542.8M
Total Debt/Equity (mrq)
93.77%
Levered Free Cash Flow (ttm)
173.89M
Research Analysis: PRGO
View MoreCompany Insights: PRGO
PRGO does not have Company Insights
Research Reports: PRGO
View MoreThe Argus Mid-Cap Model Portfolio
Small- and mid-cap stocks (SMID), despite bursts of outperformance, have underperformed large-caps year to date - as they have over the past five years. But they may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from unrest in the Middle East, the Russian invasion of Ukraine, issues in China, or other geopolitical developments. As well, the prices of SMID stocks generally are lower than the prices of large-caps. SMID stocks can be risky, but despite those risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 20% of the U.S. stock market's capitalization is comprised of SMID stocks.
Meaningful improvement expected in the second half
Perrigo, founded in 1887, is a leading manufacturer of generic over-the-counter healthcare products and supplier of infant formulas for the store-brand market. Perrigo's private-label consumer products encompass a variety of cold/allergy, gastrointestinal, first aid, motion sickness, vitamin, smoking cessation, and other remedies. The company has a market cap of approximately $4 billion after divesting its RX pharmaceutical business in 2021. Headquartered in Dublin, Ireland, Perrigo has over 9,100 employees.
RatingPrice TargetStocks are up. Fed Chairman Powell injected some rocket fuel into the market
Stocks are up. Fed Chairman Powell injected some rocket fuel into the market by saying, 'the time has come' to start cutting interest rates. The S&P 500 rose 1%, while the Dow gained 0.9% and the tech-heavy Nasdaq Composite was up 1.1%. The Russell 2000 added 3.3%. Both crude oil and gold were also up.
Perrigo Earnings: Sales Keep Slipping, but Recovery Underway; Second Half May Show Improvement
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
RatingPrice Target